Key Highlights
• Total recruitment for the emu™ Pivotal Validation Trial has surpassed 200 patients across Training and primary analysis cohorts, with record recruitment in July 2026.
• Mayo Clinic clinicians will present preliminary findings from an Early Experience paper on the emu™ at the 18th Annual Mayo Clinic Stroke Review in October 2026.
• FDA pre-submission (Q-Sub) engagement is planned on a proposed acute ischaemia detection endpoint, potentially saving up to two years and multi-million dollar costs.
• Full trial enrolment is targeted for early CY2027, with sequential cohort readouts to follow, underpinning the planned FDA De Novo clearance pathway.
EMVision Medical Devices Limited (ASX:EMV), an Australian medical device company developing point-of-care neurodiagnostic technology, reported on 31 August 2026 that total enrolment in its emu™ Pivotal (Validation) Trial has surpassed 200 patients across both training and primary analysis cohorts. The milestone was reached following record recruitment in July 2026, supported by trial ramp-up initiatives, protocol enhancements and expanded hours of coverage at participating hospital sites. As at 31 August 2026, EMV shares were trading at $1.70, up 1.50% on the day.
The emu™ is EMVision's first-generation point-of-care Brain Scanner designed to enable earlier triage, transfer and treatment decisions at the bedside for time-sensitive medical emergencies including stroke. The device's design allows it to detect haemorrhagic stroke — bleeding in the brain — at the point of care, where conventional imaging such as CT or MRI may not be immediately accessible.
Trial Design and Primary Endpoint
The Pivotal Trial is a multi-centre, prospective, blinded diagnostic study designed to support U.S. Food and Drug Administration (FDA) De Novo clearance of the emu™. The primary objective is to demonstrate haemorrhage detection sensitivity and specificity of greater than 80%. The study is designed with training, verification and primary analysis cohorts — the primary analysis cohort requires 300 patients, split into two arms of 150 intracranial haemorrhage patients and 150 other cases.
Participating sites include Mayo Clinic in Florida, Mount Sinai Hospital and Mount Sinai West in New York, Ronald Reagan UCLA Medical Center in California, Memorial Hermann in Texas, Royal Melbourne Hospital in Victoria and Liverpool Hospital in New South Wales. Princess Alexandra Hospital in Queensland is transitioning into the Trial from the company's separate Continuous Innovation Study.
Expanded FDA Engagement: Adding Ischaemia Detection
A strategically significant development in the current update is the planned addition of an acute ischaemia detection endpoint to the trial alongside haemorrhage detection. Ischaemic stroke — caused by blocked blood vessels — accounts for the majority of stroke presentations and requires a different treatment approach from haemorrhagic stroke. Currently, the trial is designed to demonstrate haemorrhage detection only.
By incorporating ischaemia detection into the same trial rather than conducting a separate validation program, the company estimates it could save up to two years and multi-million dollar costs. This approach would also enable the emu™ to address both major stroke types from initial regulatory clearance, expanding clinical Utility and the addressable patient population. FDA pre-submission (Q-Sub) engagement on the proposed ischaemia endpoint is planned for the coming months.
Mayo Clinic Presentation and Clinical Community Engagement
Mayo Clinic clinicians will present preliminary findings from an Early Experience paper on the emu™ Brain Scanner at the 18th Annual Mayo Clinic Stroke and Cerebrovascular Disease Review in Amelia Island, Florida, in October 2026. EMVision will also participate in a technology showcase at the conference, providing an opportunity for direct engagement with the U.S. stroke community ahead of planned commercialisation.
Separately, EMVision technology was prominently featured at the Australia and New Zealand Stroke Organisation Conference 2026 in Brisbane, with clinician-led presentations on the pivotal validation of the emu™ and on interpretable AI algorithms for stroke assessment. Clinician advocacy and peer-reviewed presentation at major scientific forums are considered important elements of building awareness prior to commercial launch.
Continuous Innovation Study and AI Development
Running in parallel with the Pivotal Trial, EMVision's Continuous Innovation Study has recruited more than 150 patients across multiple Australian sites. This study provides cost-effective training data to support ongoing development of the AI diagnostic models used in the emu™. Under the Pivotal Trial protocol, EMVision is only required to provide the AI diagnostic model at the conclusion of patient enrolment, meaning the team can continue refining algorithms — including incorporating additional training data — until an algorithm freeze ahead of the blinded performance analysis.
A software development project (ADP Project) completed within the 4D data processing platform — noted in a separate but related context — has enhanced processing efficiency and expanded capacity to support operational scalability from existing infrastructure. EMVision has offices in Sydney and Brisbane.
Conclusion
EMVision's 200-patient milestone in its Pivotal Trial represents tangible progress toward the FDA De Novo clearance pathway for the emu™ Brain Scanner. The proposed addition of an ischaemia detection endpoint, if supported by the FDA, could substantially increase the device's commercial relevance and reduce the overall time and cost to regulatory clearance. With full enrolment targeted for early CY2027 and sequential cohort readouts to follow, the next 12 to 18 months will be a critical period for the company's regulatory and commercial development timeline. Investors should note that the company is at the pre-revenue, development stage and that trial outcomes, FDA decisions and commercialisation timelines are subject to significant uncertainty.
Frequently Asked Questions (FAQs)






Please wait processing your request...